Alexion Pharmaceuticals (NASDAQ:ALXN) reported Q4 2017 earnings this Morning, coming in at $1.48 per share, beating Wall Street’s estimates of $1.27 per Share. Revenue for the quarter came in at $909.70 million beating analyst estimates of $880.38 million Recent Insider Trading for Alexion Pharmaceuticals (NASDAQ:ALXN)
- On 2/5/2018 Heidi L Wagner, SVP, sold 655 with an average share price of $117.26 per share and the total transaction amounting to $76,805.30.
- On 2/5/2018 John B Moriarty, EVP, sold 1,261 with an average share price of $117.26 per share and the total transaction amounting to $147,864.86.
- On 1/2/2018 Ludwig Hantson, CEO, sold 2,553 with an average share price of $121.63 per share and the total transaction amounting to $310,521.39.
- On 10/2/2017 Heidi L Wagner, SVP, sold 120 with an average share price of $140.00 per share and the total transaction amounting to $16,800.00.
- On 9/5/2017 Ann M Veneman, Director, sold 835 with an average share price of $145.81 per share and the total transaction amounting to $121,751.35.
- On 9/5/2017 Julie O’neill, EVP, sold 4,375 with an average share price of $145.44 per share and the total transaction amounting to $636,300.00.
Recent Trading for Alexion Pharmaceuticals (NASDAQ:ALXN) Shares of Alexion Pharmaceuticals closed the previous trading session at 116.31 down -0.84 0.72% with 116.30999755859375 shares trading hands.